Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | ANPEP | P15144 | 3/20 | 0.38 |
| ▸ | DNPEP | Q9ULA0 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20353108 | 1.00 | KMT2A (0.61) | KMT2AMEN1ANPEPDNPEPCYP2C19 | |
| SCHEMBL27097937 | 1.00 | KMT2A (0.61) | KMT2AMEN1ANPEPDNPEPCYP2C19 | |
| SCHEMBL16248577 | 0.98 | KMT2A (0.58) | KMT2AMEN1ANPEPDNPEPCYP2C19 | |
| SCHEMBL10447931 | 0.90 | KMT2A (0.73) | KMT2AMEN1CYP2C19CYP2D6CYP2C9 | |
| SCHEMBL18908735 | 0.90 | KMT2A (0.73) | KMT2AMEN1CYP2C19CYP2D6CYP2C9 | |
| SCHEMBL18908674 | 0.90 | KMT2A (0.73) | KMT2AMEN1CYP2C19CYP2D6CYP2C9 | |
| SCHEMBL21106195 | 0.89 | KMT2A (0.58) | KMT2AMEN1ANPEPDNPEPCYP2C19 | |
| SCHEMBL21106194 | 0.89 | KMT2A (0.58) | KMT2AMEN1ANPEPDNPEPCYP2C19 | |
| SCHEMBL24379950 | 0.89 | KMT2A (0.58) | KMT2AMEN1ANPEPDNPEPCYP2C19 | |
| SCHEMBL12387741 | 0.88 | KMT2A (0.69) | KMT2AMEN1CYP2C19CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295097-A1 | LIPIDIC COMPOUNDS COMPRISING AT LEAST ONE TERMINAL RADICAL OF FORMULA -NH-CX-A OR -NH-CX-NH-A, COMPOSITIONS CONTAINING THEM AND USES THEREOF | SANOFI PASTEUR (FR) | 2023-09-21 | — | — | US | disclosed |
| US-20230158150-A1 | COMPOUND COMPRISING A NUCLEIC ACID AND A HALF-LIFE EXTENSION MOTIF | NOVARTIS AG (CH) | 2023-05-25 | — | — | US | disclosed |
| US-20230158150-A1 | COMPOUND COMPRISING A NUCLEIC ACID AND A HALF-LIFE EXTENSION MOTIF | NOVARTIS AG (CH) | 2023-05-25 | — | — | US | disclosed |
| WO-2023004163-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK WITH ENHANCED IMID ACTIVITY | NURIX THERAPEUTICS, INC. (US) | 2023-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295097-A1 | LIPIDIC COMPOUNDS COMPRISING AT LEAST ONE TERMINAL RADICAL OF FORMULA -NH-CX-A OR -NH-CX-NH-A, COMPOSITIONS CONTAINING THEM AND USES THEREOF | PRDX5, ANXA5, PRDX1 | KMT2A 3214/4885MEN1 4505/4885ANPEP 2191/4885 |
| US-20230158150-A1 | COMPOUND COMPRISING A NUCLEIC ACID AND A HALF-LIFE EXTENSION MOTIF | NSUN2, NSUN3, POLM | KMT2A 1230/4885MEN1 1278/4885ANPEP 634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.